Your browser doesn't support javascript.
loading
Establishing a risk stratification model to identify clinically high-risk N0 breast cancer who could benefit from regional nodal irradiation: a single institute analysis.
Qi, Wei-Xiang; Cao, Lu; Ou, Dan; Li, Shuyan; Xu, Cheng; Cai, Rong; Xu, Haoping; Cai, Gang; Chen, Jiayi.
Affiliation
  • Qi WX; Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Cao L; Shanghai Key Laboratory of Proton-therapy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Ou D; Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Li S; Shanghai Key Laboratory of Proton-therapy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Xu C; Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Cai R; Shanghai Key Laboratory of Proton-therapy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Xu H; Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Cai G; Shanghai Key Laboratory of Proton-therapy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Chen J; Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Oncol ; 14: 1290852, 2024.
Article in En | MEDLINE | ID: mdl-39346731
ABSTRACT

Background:

The purpose of this real-world study was to investigate the risk factors for developing recurrence among patients with pathological T1-3N0 breast cancer (BC) treated with breast-conserving surgery (BCS) followed by whole breast irradiation alone (WBI) and identify those clinically high-risk BCs who could benefit from regional nodal irradiation (RNI). Materials and

methods:

Female BC patients treated at Shanghai Ruijin hospital from 2009 to 2016 were retrospectively reviewed. The disease-free survival (DFS), breast cancer specific survival (BCSS) and overall survival (OS) were estimated by the Kaplan-Meier method, and survival differences were compared with the log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazards regression analysis. An external validation was conducted by using SEER database.

Results:

A total of 622 BC patients treated with BCS+WBI alone were included. With a median follow-up of 82 months, the 7-year OS, BCSS and DFS for the entire cohort was 97%, 99% and 91%, respectively. Multivariable Cox analysis indicated that tumor size (p=0.006), tumor location (p=0.033), lymphovascular invasion (LVI) status (p=0.0028) and Ki-67 index (p=0.051) were independent risk factors for DFS. A scoring system was developed using these four factors and the 7-year DFS and OS were 97% and 96% for patients with 0-1 risk factors, 95% and 82% for patients with ≥2 risk factors (p<0.0001 for DFS, and p=0.0063 for OS). Based on tumor size and tumor location, an external validation by demonstrated that the 7-year OS was 90% and 88% for patients with 0-1 risk factor, which was significantly better than those defined as high-risk BC patients (82%, p<0.0001).

Conclusion:

By using our institute database, we establish a risk stratification system for identifying sub-group of pN0 BC patients, who are at high risk for developing recurrence. The results of our study support tailored RT decision-making according to individual risks, which needed to be confirmed in further studies.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: China Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: China Country of publication: Switzerland